FIGURE LEGENDS
Figure 1: Sample Population Characteristics. This study included a cohort of 87 patients with serum sample collection at infancy (Y1), 1-year follow-up (Y2), and 4 years later (Y5). Samples collected from children diagnosed with dermatitis for this study have been previously described and assessed for clinical features including asthma [9].
Figure 2: Correlations to SCORAD. (a) Repeated measurement correlation of SCORAD to the concentration of all analytes across all study years. (b) Log2 protein expression of serum protein concentrations correlated to SCORAD for key analytes of interest. 1= year 1; 2= year 2; 5= year 5.
Figure 3: Analyte Patterns in the Population. (a, b) Volcano plot showing serum protein change from Y1. Proteins expressed at Y1 that decrease in Y5 or Y2 are colored blue. Proteins expressed at Y1 that increase at Y5 or Y2 are colored red. (c) Log2 protein expression of serum protein concentrations for key analytes of interest. *significant change from Y1, p-value <0.05; Y1= year 1; Y2= year 2; Y5= year 5.
Figure 4: Correlations Among Cytokines. (a) Heatmap representation of cytokine correlations to one another shown with additional proteins of interest across the course of the study. (b) Visual representation of cytokine correlations to each other (thickness of connecting line) and to SCORAD (size of circle) across all time points of the study. Red color denotes correlations ≥0.35. Blue color denotes correlations ≤0.35.
Figure 5: Pathway analysis. (a) Top 10 pathway maps for highly expressed proteins at year 1 that decrease expression by year 5. The 28 specific proteins used for this analysis are outlined in Figure 3a. (b) Top 10 pathways of most highly expressed proteins at year 5 that were low or absent at year 1. The 6 specific proteins used for this analysis are outlined in figure 3a. (c) Heat map correlations of cell phenotypes previously assessed by flow cytometry [11] to serum protein analysis from same time point.
Figure 6: Predictive Model. (a) Using forward modeling with AIC, we use the listed 18 serum analytes to predict change in SCORAD over time. The fit of these 18 analytes within this model are defined by root mean square error (RMSE) and R square adjusted (R2). (b) Samples were split into either test or training sets to assess the reproducibility of the model.
Supplemental Figure 1: Analyte Patterns in the Population. Log2 protein expression of serum protein concentrations for analytes of interest. Y1= year 1; Y2= year 2; Y5= year 5.
Supplemental Table 1: Correlations to SCORAD and Among Cytokines . Repeated measurement correlations of SCORAD to the concentration of selected analytes and correlations of cytokine correlations to one another across all study years.
REFERENCES
1. Weidinger, S., et al., Atopic dermatitis. Nat Rev Dis Primers, 2018. 4 (1): p. 1.
2. Silverberg, J.I., Adult-Onset Atopic Dermatitis. J Allergy Clin Immunol Pract, 2019. 7 (1): p. 28-33.
3. Weidinger, S. and N. Novak, Atopic dermatitis. The Lancet, 2016. 387 (10023): p. 1109-1122.
4. Spergel, J.M. and A.S. Paller, Atopic dermatitis and the atopic march. J Allergy Clin Immunol, 2003. 112 (6 Suppl): p. S118-27.
5. Bieber, T., et al., Unraveling the complexity of atopic dermatitis: The CK-CARE approach toward precision medicine. Allergy, 2020.
6. Brunner, P.M., et al., The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol, 2019.81 (2): p. 510-519.
7. Czarnowicki, T., et al., Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol, 2020. 145 (1): p. 215-228.
8. Bohme, M., et al., Family history and risk of atopic dermatitis in children up to 4 years. Clin Exp Allergy, 2003. 33 : p. 1226-1231.
9. Tepper, R.S., et al., Expired nitric oxide and airway reactivity in infants at risk for asthma. J Allergy Clin Immunol, 2008.122 (4): p. 760-765.
10. Yao, W., et al., Evaluation of airway reactivity and immune characteristics as risk factors for wheezing early in life. J Allergy Clin Immunol, 2010. 126 (3): p. 483-8 e1.
11. Yao, W., R.S. Tepper, and M.H. Kaplan, Predisposition to the development of IL-9-secreting T cells in atopic infants. J Allergy Clin Immunol, 2011. 128 (6): p. 1357-1360 e5.
12. R: A language and environment for statistical computing.2013; Available from: http://www.R-project.org/.
13. JMP14 . 2018 [cited 1989-2019; Available from: https://support.sas.com/downloads/index.htm?fil=2.
14. Burnham, K.P. and D.R. Anderson, 2002 . 2 ed. Model Selection and Multimodel Inference: A Practical Information Theoretic Approach: Springer-Verlag New York.
15. Stone, M., Cross-Validatory Choice and Assessment of Statistical Predictions. Journal of the Royal Statistical Society: Series B (Methodological), 1974. 36 (2): p. 111-133.
16. MetaCore . 2020; Available from: https://clarivate.com/cortellis/solutions/early-research-intelligence-solutions/.
17. Brunner, P.M., et al., The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Scientific Reports, 2017. 7 (1): p. 8707.
18. Nograles, K.E., et al., IL-22-producing ”T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol, 2009.123 (6): p. 1244-52 e2.
19. Kiiski, V., et al., High serum total IgE predicts poor long-term outcome in atopic dermatitis. Acta Derm Venereol, 2015.95 (8): p. 943-7.
20. Hon, K.E., et al., Are age-specific high serum IgE levels associated with worse
symptomatology in children with atopic dermatitis? International Journal of Dermatology, 2007. 46: p. 1258-1262.
21. Kataoka, Y., Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol, 2014.41 (3): p. 221-9.
22. Taha, R.A., et al., Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol, 2000. 105 (5): p. 1002-7.
23. Guttman-Yassky, E., et al., Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatol, 2020.
24. Bieber, T., Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy, 2020. 75 (1): p. 54-62.
25. Black, A., et al., Developmental regulation of Th17-cell capacity in human neonates. Eur J Immunol, 2012. 42 (2): p. 311-9.
26. Yao, W., et al., Altered cytokine production by dendritic cells from infants with atopic dermatitis. Clin Immunol, 2010.137 (3): p. 406-14.
27. Davidson, W.F., et al., Report from the National Institute of Allergy and Infectious Diseases workshop on ”Atopic dermatitis and the atopic march: Mechanisms and interventions”. J Allergy Clin Immunol, 2019. 143 (3): p. 894-913.
28. Grinnan, D., et al., Enhanced allergen-induced airway inflammation in paucity of lymph node T cell (plt) mutant mice. J Allergy Clin Immunol, 2006. 118 (6): p. 1234-41.
29. Trella, E., et al., CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells. Eur J Immunol, 2016. 46 (2): p. 420-31.
30. Thijs, J.L., et al., A panel of biomarkers for disease severity in atopic dermatitis. Clin Exp Allergy, 2015. 45 (3): p. 698-701.
31. Grünig, G., et al., Interleukin 13 and the evolution of asthma therapy. Am J Clin Exp Immunol, 2012. 1 (1): p. 20-27.